Ardelyx
Latest round
- Series B
Last raised
- Jun 2011
Total raised
- $44M
Investors
- 3
About Ardelyx
Ardelyx, Inc.Founded in 2007 in Fremont, US, Ardelyx, Inc. specializes in the development of therapeutics for chronic kidney disease and gastrointestinal disorders. The current CEO is Mike Raab. The company has completed a total of 10 deals, with the most recent deal dated June 19, 2014.Ardelyx, Inc. develops first-in-class medicines focused on chronic kidney disease and gastrointestinal disorders, including treatments for hyperphosphatemia and irritable bowel syndrome with constipation (IBS-C).In the most recent fiscal year 2024, Ardelyx reported revenue of USD 319,196 and an EBITDA of USD -25,887. The company is also looking to expand into new markets, focusing on broader distribution in the United States and targeting select international regions to enhance accessibility to its products.
Who invested in Ardelyx
3 investors across 2 rounds
See all investors in Ardelyx
Sign up free to see every VC on the cap table, the rounds they joined, and how much each round raised.
Questions about Ardelyx
Who invested in Ardelyx?
Ardelyx has 3 investors on record across 2 venture rounds. Sign up free to see every VC on the cap table and the rounds they joined.
How much funding has Ardelyx raised?
Ardelyx has raised 2 venture rounds. Sign up free to see how much each round raised and the total.
When did Ardelyx last raise money?
Ardelyx's most recent round on record is a Series B, in Jun 2011.
What does Ardelyx do?
Ardelyx is a pharmaceuticals company.
Where is Ardelyx headquartered?
Ardelyx is headquartered in Fremont, US.
Which VCs invest in companies like Ardelyx?
Among active investors with capital left to deploy, Andreessen Horowitz, Founders Fund, Accel and Thrive Capital back pharmaceuticals companies at Ardelyx's stage. Their profiles are linked below.
VCs backing pharmaceuticals startups at Series B
Raising like Ardelyx? Find the right VCs.
Capital Atlas matches your startup to active investors by stage, sector and region.